Phase IV clinical trial of CEDARCURE(R)SLIT-tablet and MITICURE(R)SLIT-tablet. - Evaluation of safety in patients with both Japanese cedar pollinosis and HDM-induced allergic rhinitis.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Sep 2018
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary) ; Japanese cedar pollen allergy immunotherapy ALK Abello/Torii Pharmaceutical (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Torii Pharmaceutical
- 28 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Jul 2018 New trial record